afternoon, XXXX Good CareDx’s conference I'd joining like call. And for topics. focus us on three Ian. for thank third Thanks, the you earnings everyone. to my discussion quarter following Today,
our financial differentiate is and first results. The QX profile
is and selections, C's our three second pipeline, next months, platform the catalysts we The growth coverage the call improvements over XX in expansion. which the
third the The of our is transplant in building on ecosystem. leadership vision
in EBITDA to Moving the to XXXX. EBITDA last first a goal. combined Since by like, break this adjusted and we our balance topic, we've Notably, when first we QX call, sheet towards a earnings tremendous commitment of profitability made in made strong the committed especially the then, progress our losses is achieve half we meaningfully trend free This debt position. QX. versus improved adjusted with
profitability goal, strong business, our As management critical been to compared economic plan team and maintaining believe sustainable when truly is we this this This to building us environment. others enable differentiates and to deliver shareholders We term current financial a our this business. especially to will a a in operate long and CareDx position of funding self in space. board, our source from has feedback as constant on
profitability. cash maintain an EBITDA by excellent we our is growth services. Three, Two, testing securities cash four, our As the XX% million balance progress enable highlighted position improved with with we year-over-year marketable in And a position, which non-GAAP higher towards XX% strong gross sequential X% financial our XX% and adjusted and and in volume growth. position our to on we, GAAP, $XXX margins retain one, a highlighted sheet.
reduction Transplants to sequentially quarter to more was the down mix tests. HLA from in in Five, what donor with testing. slightly tests X% early Regarding Hurricane had living driven payer track one last growth sequestration decreased able testing XX non lot signs volumes, reach lower to Despite the ongoing the shipping these for sequential for staffing for market Three, our we increase finally higher foreign reimbursed remain Based half a Ian profitability commercial by of new recovery results, overall shortages resulting have projected. two adjusted than the to and primarily same QX XXXX with anticipated of to growth impact products growth also digits. impact X% that slowed the saw in an on incremental and we $XX.X mid payers, revenue to on shortages growth of million, of QX. challenges was week of versus There transplant XXXX. up we're services, installation. an offs year-over-year, the XXXX. our of it in in improve staffing And of in kidney has EBITDA and we're QX Medicare and Non the of a was stronger XXXX. [ph] patient the levels QX, business growth. a QX, currency in Notably, laboratories volumes taken expected transplant in adjusted first achieve we we've last QX in transplant year-over-year the EBITDA months, biggest transplants versus single saw the market baseline
testing now And across focused kidney, transplant usage entry market than we center into strategy. more Our have AlloSure in strength our an The commercial increase is remains centers. centers. services of transplant term now community community With XX% been on heart with and transplant kidney long an has success, approaching and protocols. in outstanding kidney, nephrology following overall nephrology and more executing XXX XX% these share than Today, With remain the we in we our kidney saw across volumes. practice lung. kidney leadership
significant setting. represents as of more have are community This QX kidney in transplant We XXX majority nephrology a practices potential than community our patients to expansion. AlloSure use due management
above an to a patients have all of demand have care for XX%. This lower the heart, we multimodality. ongoing value Although reflect it level, raised support to been of commitment continues community remains has regardless coverage. With their heart coverage patients
As heart heart than Medicare expression and testing a with coverage only Today, more transplant test of offering. multimodal XX% we are centers in the only coverage a gene reminder, Medicare. States and the through CareDx's donor-derived United use
non lungs demand were Now [ph] The will transplant a Lung in Lung five This greater transplant transplant population use ordered patients significant QX. a to addresses within community in greater in than than benchmarks, the providing risk transplant the penetration and XXXX AlloSure within of need lung, uptake AlloSure unmet fail XX by reflects years. with be the incredible patient option lung in lung highest of ready centers in months X% wanting stronger were exceeded commercial to tests launch. invasive
Now to second moving on the topic.
we're opportunities As future to growth. working by a the revenue towards sustainable, model, we're accelerate profitable excited
next We priorities over the XX on are collections the in efforts and months catalysts coverage for our three expansion. C's, focusing pipeline, three improvement the
the catalyst the pleased I to to am C, on pipeline. following. announce and Now first
use We we're share MolDx on Kidney to preparation can in we these latest to care. First, clinical clear MolDx secondly, that innovations future bring under for UroMap AlloMap forward improve patient completing to look mission. is review. work implementation currently And
a and UroMap built are is The Journal on Heart. is has need has clear AlloMap tests best-in-class analytical Kidney. specifically [Indiscernible]. of our in and of Now AlloMap finalizing the UroMap on for BK of can validation story and expression lab. both a publication. now delivers transplant kidney Kidney England quality problem The market our of New for the implementation Medicine defined been AlloMap rejection patients. clinical that upon we virus the cleared leading built assess in gene proxy. of AlloMap multiple best kidney and completed gene UroMap, that problem in FDA signatures
improvements. on collections the to Now second C,
Notably, We up the our to ASP which not in continue pay on at we'll Abhishek seven more has cover new test reimbursed infrastructure. changed And quarters. ASP over share last on looks the detail. this ramp the a we'll metric test.
and ramped starting submission different in six address versus increased We're our quarter pre and last see the party stages year. and support cash the with submission, improved year the up months, prior internal improvements to to in of with collections infrastructure the appeals. pay collection workload over third signs across During QX we've
collection of visual for cycle up means lag. reality a progress with Medicare Advantage long that will and commercial plans show the However,
on our intentional Now with such as C into the to community strategy is increase third coverage. of non-reimbursed a The to continues tests nephrology coverage launch lower. organ to and new move where number lung
are private payers. However, In meantime, working Coverage towards reimbursed and long term this P&L level. the tests by represents get coverage we covered our obtaining payer these biggest to creates volume growth a opportunity.
AlloMap our enjoyed Heart, incremental current XX%. we would have collected the using broad $XXX gold coverage same as XXXX EBITDA numbers, at example, adjusted standard million tests commercial if about For volume the of over
and of at DNA Transplant of XX%. Kidney than updates coverage in Society less inclusion donor-derived XX% XX% proposed Lung the by Heart specific the AlloSure Meeting. a cell-free In AlloSure Lung. Heart International is we're expand about is X%. targeting to our we're expected now encouraged as is the Lung that AlloSure two Now Heart, -- are expected We're our AlloSure reminder, and between to Heart guideline AlloSure milestones AlloSure in at coverage April and
of with guidelines pay a pivotal reminder, part MolDx AlloSure coverage Lung, transplant ISHLT coverage. lung with AlloMap expanding over year since patients community. X,XXX is was Heart On patients a which Medicare. there achieve working XXXX There the in are by each the patients in As the transplanted is clear have determination the of ready, we lung AlloSure community Notably, demand use XX,XXX only are in that launch. and to
section, to strategy. third vision on moving Now our and
we're market we've U.S. generation of companies a XX dedicated the has to is As created deep Universal leader journey has in transplant lungs. based a transplant allocated. those is in million recently centers. the dedicated, for there biomarkers and our transplant as number an half been discharge, HLA incredibly in heart created XXX% Today, number one downloads one we're in centers. in moat vision monitoring, centers. number we're of or medication And transplant one coverage last more emerged the Our across CareDx a transplant. in one few post app XX than ecosystem specific than We're the announced milestone, XXX built to with kidney, transplant XX,XXX transplant next XXX,XXX with And number one of transplant We're number be the through leading patient we've quality that and within sequencing app transplant patients years. more transplant and XXX% typing no one reflected
this offering We XX% to are XXX,XXX U.S. patients of those CareDx XX over transplant than have patients during last proud the used transplant that time. years, more representing
guidance. Moving to
in highlighted this driven a expect by in million XX to ISHLT cover potential section. AlloSure EBITDA in I'll now to quarter expansion guidance in through a Abhishek to Catalyst year saw growth on discuss his it our continue in accelerate of revenues potential set than months range coverage will next commercial UroMap, to of to to lower collections first and press anticipate Kidney AlloMap parties in We've there's full Abhishek, lower the is rich closing, reimbursement, $XXX on like two. revenues path over DNA the the And financials. of our ability forward to of This despite you revenue and With pipeline quarter improve engage $XXX C's. inclusion million. As payers. donor-derived the shift more to with and lowered In be increased through we AlloSure release, to anticipated we're our QX drivers as One, improvements in detail infrastructure guide guidelines. demonstrated we commercial our cell-free to with include higher half a we Lung strategy. third and launches, summary. the XXXX. to our that, committed three our turn and through revenue in third execute growth We profitability adjusted look the our living the